In a notable development, GLP-1 agonists, such as Ozempic, are displaying potential beyond their established roles in diabetes and obesity management.
This newfound potential is evident in the case of Jeannine Manning, who, following the initiation of Ozempic treatment for type 2 diabetes and weight management, achieved significant weight loss and a remarkable improvement in her symptoms of sleep apnea.
Previously reliant on a CPAP machine to manage her obstructive sleep apnea (OSA), Manning observed a substantial reduction in her sleep apnea symptoms, accompanied by a decline in snoring, as a result of her weight loss.
OSA, the most prevalent form of sleep apnea, is often exacerbated by factors such as obesity. The reduction of fat tissue in the neck and abdominal area through weight loss appears to alleviate these symptoms.
Experts like Sethu Reddy, MD, the president of the American Association of Clinical Endocrinology, find Manning\’s experience in line with existing knowledge of the relationship between obesity and breathing mechanics.
However, both Reddy and other experts emphasize the need for further research and clinical trials before considering the prescription of GLP-1 medications as a treatment for OSA. Additional investigation is crucial to solidify these promising findings and establish guidelines for the use of GLP-1 medications in sleep apnea management.
